The mission of the Cancer Cell Biology and Signaling (CCBS) Program is to elucidate the role of cell signaling in regulating cell growth, differentiation, apoptosis and migration, and to assist Cancer Center members in their efforts to harness this understanding into approaches to cancer detection, prognosis and treatment. Program members focus on three major areas of research: 1) understanding the molecular mechanisms involved in the regulation of cell growth and differentiation with an emphasis on the role of tyrosine kinase and G protein-coupled receptor signaling pathways;2) elucidating the molecular mechanisms regulating cell apoptosis;and 3) addressing the role of the extracellular matrix in regulating cell growth and migration. The Program is led by Drs. Jeffrey Benovic and George Prendergast, both of whom have extensive administrative experience and established research programs focused on cell signaling and cancer. The Program is comprised of twenty-three members and one associate member from nine departments and three Institutions (Jefferson, Lankenau Institute for Medical Research and Drexel). Program members currently have $3.4 million of NCI support and $12.0 million of total, peer-reviewed support and have published a total of 650 manuscripts (11% intra-programmatic and 26% inter-programmatic) during the last funding period.

Public Health Relevance

An important scientific goal of the CCBS Program is to integrate fundamental studies on the mechanisms that regulate cell growth, differentiation, apoptosis and migration with the translational research efforts at the KCC. This should result in a better understanding of the biology of cancer and also in translation of basic research into novel therapeutic strategies for the treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA056036-14
Application #
8517953
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-15
Project End
2018-05-31
Budget Start
2013-06-18
Budget End
2014-05-31
Support Year
14
Fiscal Year
2013
Total Cost
$29,667
Indirect Cost
$10,511
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Sullivan-Reed, Katherine; Bolton-Gillespie, Elisabeth; Dasgupta, Yashodhara et al. (2018) Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep 23:3127-3136
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Lapadula, Dominic; Farias, Eduardo; Randolph, Clinita E et al. (2018) Effects of Oncogenic G?q and G?11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res :
Vite, Alexia; Zhang, Caimei; Yi, Roslyn et al. (2018) ?-Catenin-dependent cytoskeletal tension controls Yap activity in the heart. Development 145:
McNair, Christopher; Xu, Kexin; Mandigo, Amy C et al. (2018) Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest 128:341-358
Garcia, Samantha A; Lebrun, Aurore; Kean, Rhonda B et al. (2018) Clearance of attenuated rabies virus from brain tissues is required for long-term protection against CNS challenge with a pathogenic variant. J Neurovirol 24:606-615
Vido, Michael J; Le, Kaitlyn; Hartsough, Edward J et al. (2018) BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep 25:1501-1510.e3
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469
Liao, Lili; Liu, Zongzhi Z; Langbein, Lauren et al. (2018) Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. Elife 7:
Heeke, Arielle L; Pishvaian, Michael J; Lynce, Filipa et al. (2018) Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018:

Showing the most recent 10 out of 807 publications